Goserelin Treatment and Blood Loss Associated with Transurethral Resection of the Prostate by Ipekci, Tumay et al.
Journal of Clinical and Analytical Medicine | 1
Ed
it
ör
’e M
ektup
Letters to Edito
r
Goserelin ve Prostatın Mikrovasküler Dansitesi / Goserelin and Microvessel Density in Prostate
Tümay İpekçi1, Betül Ünal2,  Mustafa Burak Hoşcan1
1Başkent University, Faculty of Medicine, Department of Urology, Alanya Practice and Research Center, 
2Akdeniz University, Faculty of Medicine, Department of Pathology, Antalya, Turkey
Goserelin Treatment and Blood Loss Associated with 
Transurethral Resection of the Prostate
Goserelin Tedavisi ve Prostatın Transüretral 
Rezeksiyonu ile İlişkili Kan Kaybı
DOI: 10.4328/JCAM.2449  Received: 31.03.2014 Accepted: 31.03.2014 Printed: 01.05.2015
Corresponding Author: Mustafa Burak Hoşcan, Baskent University Alanya Research and Practice Center, Department of Urology Alanya, Antalya, Turkey.
GSM: +905324364855 F.: +90 2425115563 E-Mail: drburakhoscan@yahoo.com
To the editor:
We have read the article in which investigated the microvascular density (MVD) in the sections of transurethral resection 
materials and blood loss during the operation of benign prostate hyperplasia cases to whom goserelin is applied before the 
treatment with great interest [1]. In numerous studies; it is specified that new vessel formation has an important role in tumor 
enlargement, development and also metastasis [2,3]. As in the malignant solid tumors; significant angiogenesis namely micro-
vascular density is observed in benign lesions like prostate hyperplasia. Its importance is that it can cause increased blood loss 
during the operation due to the easy decomposition feature of new formed proliferated vessel structures. In order to prevent 
this; preoperative 5alpha reductase inhibitor (finasteride) or gonadotropin releasing hormone analogue (goserelin) can be used 
and the suppression of angiogenesis can be wise. In the literature; it is specified that angiogenesis in BPH has a critical impor-
tance and angiogenesis can be suppressed by androgen suppression [4]. Immunohistochemically; numerous indicators can be 
used in the measurement of microvascular density such as CD31, CD105, CD144, CD146, CAV1 and VEGFR2 besides CD34 [5]. 
In some of the studies; normal prostate tissue and prostatic adenocarcinoma are compared and it has drawn attention that 
CD34 positive capillary network has shown an increase [6]. In the study; no significant relationship is found between the total 
blood loss and MVD which are observed throughout TUR-P. Because of that single dose depot 3.6 mg Goserelin application is 
not recommended before TUR-P, and they have recommended long-term treatments that will decrease the testosterone level to 
the castration level. However the remarkable case in the study results is that in Group 1, in other words the patients receiving 
treatment, MVD quantity is determined as significantly higher. According to our opinion; in case the treatment is not efficient; 
MVD ratio could be close to the ratio of Group 2 but there is a confusing situation in this case. Thus, it was reported that GnRH 
analogues decrease VEGF release and suppress angiogenesis [7] .So the immunohistochemical technical-evaluation that is ap-
plied to evaluate MVD2 should be investigated or besides CD34; at least one of the above mentioned microvessel indicators 
should be added to the method. 
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